-+ 0.00%
-+ 0.00%
-+ 0.00%

Caris Life Sciences Publishes Q3 2026 Financial Results Presentation

PUBT·11/04/2026 21:26:53
Listen to the news
Caris Life Sciences Publishes Q3 2026 Financial Results Presentation
  • Caris Life Sciences reported third-quarter 2026 revenue of $275.4 million, up 27% year over year.
  • Clinical case volume rose 21% to approximately 61,500; molecular profiling revenue increased 27% to $262.7 million.
  • Adjusted EBITDA reached $44.4 million, marking a sixth consecutive positive quarter; GAAP net income totaled $15.3 million.
  • Nine-month revenue totaled $755.2 million; cash and securities stood at $769.2 million.
  • Caris Assure therapy response monitoring launched, with Caris Confirm minimal residual disease testing scheduled for December 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.